摘要
目的:从"疫毒夹湿"角度探讨加味达原方治疗新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19)疫毒闭肺证患者的临床疗效。方法:收集2020年1月31日至3月3日在武汉红十字会医院住院的COVID-19疫毒闭肺证患者45例,其中治疗组22例给予常规治疗(支持治疗、对症治疗、抗病毒等)联合加味达原方,对照组23例仅给予常规治疗,治疗7天后比较两组患者主要症状(发热、咳嗽、乏力、胸闷喘息、腹胀便秘、舌象)好转情况及外周血淋巴细胞百分比、白细胞计数、C反应蛋白、CT等变化情况。结果:与对照组比,治疗组患者主要症状(发热、咳嗽、乏力、胸闷喘息、腹胀便秘、舌象)均显著好转,治疗组患者外周血淋巴细胞百分比显著升高,C反应蛋白明显降低,CT好转率优于对照组,差异均具有统计学意义(P<0.05)。两组患者外周白细胞计数无显著差异(P>0.05)。结论:加味达原方患者能明显改善COVID-19疫毒闭肺证患者临床症状,促进淋巴细胞百分比恢复,加快肺部病变吸收,本研究为从"疫毒夹湿"角度治疗该病提供了初步临床证据。
Objective:To explore the clinical efficacy of Jiaweidayuan decoction in treating New Coronavirus Pneumonia(COVID-19)patients with"Yibingbifei"syndromes from"Yidujiashi"theory.Methods:45 patients with COVID-19"Yibingbifei"syndromes who were hospitalized in Wuhan Red Cross Hospital from January 31 to March 3,2020 were collected.22 patients in the treatment group were given conventional treatments(supportive treatment,symptomatic treatment,antiviral treatment,etc.)combined with Jiaweidayuan decoction,while 23 patients in the control group were given conventional treatments only.After 7 days of treatment,the improvements of main symptoms(fever,cough,fatigue,chest tightness,wheezing,bloating,constipation,tongue characteristics)and the changes of percentage of peripheral blood lymphocyte,white blood cell count,C-reactive protein and CT situation in the patients in the two groups were compared.Results:Compared with the control group,the main symptoms(fever,cough,fatigue,chest tightness,wheezing,bloating,constipation,tongue characteristics)in the treatment group were significantly improved.The percentage of peripheral blood lymphocytes of patients in the treatment group was significantly increased,C-reactive protein was significantly reduced,and the improvement rate of CT situation was better than that in the control group,all differences were statistically significant(P<0.05).There was no significant difference in peripheral white blood cell count between the patients in the two groups(P>0.05).Conclusion:Jiaweidayuan decoction can significantly improve the clinical symptoms of COVID-19 patients with"Yibingbifei"syndromes,promote the recovery of lymphocyte percentage,and accelerate the absorption of pulmonary lesions.It also provides the preliminary clinical evidences for treating the disease from the perspective of"Yidujiashi"theory.
作者
张传涛
杨洋
由凤鸣
黄青松
高培阳
唐健元
谢春光
肖玮
孙增涛
张宏
钱斌
Zhang Chuantao;Yang Yang;You Fengming;Huang Qingsong;Gao Peiyang;Tang Jianyuan;Xie Chunguang;Xiao Wei;Sun Zengtao;Zhang Hong;Qian Bin(Respiratory Department of Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610072;Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610072;Critical Medicine Department of Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610072;Fever Ward 6 of Wuhan Red Cross Hospital(Wuhan,Hubei 430015)
出处
《中药药理与临床》
CAS
CSCD
北大核心
2020年第2期43-46,共4页
Pharmacology and Clinics of Chinese Materia Medica
基金
成都中医药大学"杏林学者"计划:"新冠病毒应急专项"(编号:XGZX2003)
四川省科技厅项目:新型冠状病毒肺炎中西医结合治疗方案研究(编号:2020YFS0013)
四川省科技厅项目:新型冠状病毒疫情下的中医药社区防控技术研究(编号:2020YFS0012)
成都市科技局项目:新型冠状病毒疫情下的中医药社区防控技术研究(编号:2020-YF05-00333-SN)。
